177-11-7

Basic information

• Product Name: 1,4-Dioxa-8-azaspiro[4.5]decane
• Synonyms: 4-Piperidone ethylene ketal, 98+%;4-Piperidone ethylene ketal 98%;1,4-DIOXA-8-AZASPIRO(4.5)DECANE (4-PIPERIDONE ETHYLENE KETAL);4,4-(Ethylenedioxy)piperidine;4-Piperidinone ethylene acetal;8-Aza-1,4-dioxaspiro[4.5]decane;Piperidin-4-one ethylene ketal;Piperidine-4-one ethylene acetal
• CAS NO: 177-11-7
• Molecular Formula: C₇H₁₃NO₂
• Molecular Weight: 143.18
• EINECS: 205-868-6
• Product Categories: Piperidine;Building Blocks;Chemical Synthesis;Heterocyclic Building Blocks;Piperidones
• Mol File: 177-11-7.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 108-111 °C26 mm Hg(lit.)
• Flash Point: 179 °F
• Appearance: Clear colorless to yellow/Liquid
• Density: 1.117 g/mL at 20 °C(lit.)
• Vapor Pressure: 0.185mmHg at 25°C
• Refractive Index: n20/D 1.4819(lit.)
• Storage Temp.: Store below +30°C.
• Solubility: DCM, Ethyl Acetate, Methanol
• PKA: 10.92±0.20(Predicted)
• Water Solubility: Soluble in water (Partly miscible).
• Sensitive: Air Sensitive
• BRN: 506799
• CAS DataBase Reference: 1,4-Dioxa-8-azaspiro[4.5]decane(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-Dioxa-8-azaspiro[4.5]decane(177-11-7)
• EPA Substance Registry System: 1,4-Dioxa-8-azaspiro[4.5]decane(177-11-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36-24/25
• WGK Germany: 3
• F: 10-34
• Hazardous Substances Data: 177-11-7(Hazardous Substances Data)

Usage

Chemical Properties

clear colorless to yellowish liquid

Uses

Different sources of media describe the Uses of 177-11-7 differently. You can refer to the following data:
1. Piperidin-4-one Ethylene Ketal is a derivative formed from the condensation of cyclohexanone.
2. 1,4-Dioxa-8-azaspiro[4.5]decane was used in the synthesis of 1,4-dioxa-8-azaspiro [4,5] deca spirocyclotriphosphazenes.

InChI:InChI=1/C7H13NO2/c1-3-8-4-2-7(1)9-5-6-10-7/h8H,1-6H2/p+1

Upstream product

• 51787-77-0 1,4-dioxa-8-aza-spiro[4.5]decane-8-carboxylic acid ethyl ester 
• 28286-05-7 8-Methyl-1,4-dioxa-8-azoniaspiro<4.5>decan 
• 1261144-91-5 8-(3,4,5,6-tetrahydropyridin-2-yl)-1,4-dioxa-8-azaspiro[4.5]decane 
• 41979-39-9 4-piperidone hydrochloride 
• 107-21-1 ethylene glycol 
• 32519-75-8 N-[5-(bromoacetyl)-4-methyl-1,3-thiazol-2-yl]acetamide, hydrobromide salt 
• 915702-31-7 ethyl 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylate 
• 915702-34-0 2'-(acetylamino)-4'-methyl-4,5'-bi-1,3-thiazole-2-carboxylic acid 
• 30748-47-1 5-acetyl-4-methylthiazole-2-amine 
• 39884-12-3 5-acetyl-2-(N-acetylamino)-4-methylthiazole 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 123387-51-9 tert-butyl 1,4-dioxa-8-azaspiro[4.5]decane-8-carboxylate 
• 42899-11-6 1,4-dioxa-8-azaspiro[4.5]decane hydrochloric acid 
• 5625-67-2 2-Ketopiperazine 

Downstream Products

• 69663-56-5 8-diphenylacetyl-1,4-dioxa-8-aza-spiro[4.5]decane 
• 18951-25-2 [3-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-propyl]-(4-phenylazo-5,6,7,8-tetrahydro-naphthalen-1-yl)-amine 
• 51787-77-0 1,4-dioxa-8-aza-spiro[4.5]decane-8-carboxylic acid ethyl ester 
• 79421-40-2 4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)benzaldehyde 
• 79421-41-3 1-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)phenyl]ethanone 
• 84157-05-1 phenyl(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)methanone 
• 190012-08-9 1-(4-methoxybenzoyl)-4-piperidone ethylene ketal 
• 122846-59-7 3-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-2-hydroxy-2-phenyl-propionic acid ethyl ester 
• 79421-38-8 4-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-benzoic acid ethyl ester 
• 79421-39-9 4-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-benzonitrile 
• 131693-15-7 N-(pentafluorobenzoyl)-4-piperidone ethylene ketal 
• 103769-38-6 2-(1,4-Dioxa-8-aza-spiro[4.5]dec-7-yl)-1-phenyl-ethanone 
• 133019-87-1 1-(4-Benzoylbenzoyl)piperidin-4-on-ethylen-acetal 
• 149633-27-2 8-[3-(4-Fluoro-phenoxy)-propyl]-1,4-dioxa-8-aza-spiro[4.5]decane 

Relevant articles and documents

NOVEL SUBSTITUTED 1,3,8-TRIAZASPIRO[4,5]DECANE-2,4-DIONE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) AND/OR TRYPTOPHAN 2,3-DIOXYGENASE (TDO) INHIBITORS

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (I). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO- and/or TDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO- and/or TDO-associated disease or disorder.

Indolyl Azaspiroketal Mannich Bases Are Potent Antimycobacterial Agents with Selective Membrane Permeabilizing Effects and in Vivo Activity

The inclusion of an azaspiroketal Mannich base in the membrane targeting antitubercular 6-methoxy-1-n-octyl-1H-indole scaffold resulted in analogs with improved selectivity and submicromolar activity against Mycobacterium tuberculosis H37Rv. The potency enhancing properties of the spiro-fused ring motif was affirmed by SAR and validated in a mouse model of tuberculosis. As expected for membrane inserting agents, the indolyl azaspiroketal Mannich bases perturbed phospholipid vesicles, permeabilized bacterial cells, and induced the mycobacterial cell envelope stress reporter promoter piniBAC. Surprisingly, their membrane disruptive effects did not appear to be associated with bacterial membrane depolarization. This profile was not uniquely associated with azaspiroketal Mannich bases but was characteristic of indolyl Mannich bases as a class. Whereas resistant mycobacteria could not be isolated for a less potent indolyl Mannich base, the more potent azaspiroketal analog displayed low spontaneous resistance mutation frequency of 10-8/CFU. This may indicate involvement of an additional envelope-related target in its mechanism of action.

PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR

This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.